Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab
The Journal of Dermatology · 2025-02 · 52 (2)
DOI: 10.1111/1346-8138.17461 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 20.09.2024. Verfasst von Hui Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province(202300410386).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
- Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
ORCID-Profile: Hui Li
Förderung
- Natural Science Foundation of Henan Province(202300410386)
Zitieren
APA
Li, H., & Wang, J. (2025). Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab. The Journal of Dermatology, 52(2). https://doi.org/10.1111/1346-8138.17461
Vancouver
Li H, Wang J. Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab. The Journal of Dermatology. 2025;52(2). doi:10.1111/1346-8138.17461
BibTeX
@article{Li2025,
author = {Li, Hui and Wang, Jianbo},
title = {Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab},
journal = {The Journal of Dermatology},
year = {2025},
volume = {52},
number = {2},
doi = {10.1111/1346-8138.17461}
}
EUVIMED